
Conference Coverage
about 1 month ago
From gene therapy to restoring sight: Highlights from EURETINA 2026about 1 month ago
EURETINA 2026: Why peripheral vision matters in macular degenerationabout 2 months ago
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026Trending on the Eye Care Network
Why ST-100 is expanding from dry eye into corneal wound healing
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
Veterinary evidence makes the case for UVC in human keratitis
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
Latest News

Shorts










Digital Edition








Podcasts
Continuing Medical Education
All News

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.

A simple stool test may reveal hidden bowel disease in patients whose only symptoms are in their eyes.

Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.

A vascular link: erectile dysfunction may signal glaucoma risk in men
An association has been identified between primary open-angle glaucoma and erectile dysfunction.

Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation choice.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.

AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.

Key takeaways on gene therapy, GA, sustained delivery and AI in Vienna

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden.

Ashish Sharma, MD, on what real-world data show about switching and long-term outcomes with retinal biosimilars.

Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.

Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.


























